BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Cidara Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-15 4:25 pm Purchase | 2025-03-31 | 13G | Cidara Therapeutics, Inc. CDTX | BIOTECHNOLOGY VALUE FUND L P | 1,252,441 9.990% | 158,942 (+14.54%) | Filing |
| 2025-02-14 4:05 pm Purchase | 2024-12-31 | 13G | Cidara Therapeutics, Inc. CDTX | BIOTECHNOLOGY VALUE FUND L P | 1,093,499 9.990% | 390,373 (+55.52%) | Filing |
| 2024-11-14 4:22 pm Purchase | 2024-09-30 | 13G | Cidara Therapeutics, Inc. CDTX | BIOTECHNOLOGY VALUE FUND L P | 703,126 9.990% | 703,126 (New Position) | Filing |